Liposomal Irinotecan and Oxaliplatin Combination Therapy for Metastatic Pancreatic Cancer

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 25th, 2026

Detected April 1st, 2026

Summary

The European Patent Office published patent application EP3791876A1 filed by Ipsen Biopharm Ltd., covering methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin. The application names eight inventors including Sarah Blanchette and Jonathan Fitzgerald. The patent designates all 31 EPC contracting states including Germany, France, UK, Italy, Spain, and the Netherlands.

View original document View source feed page

What changed

The EPO published EP3791876A1, a patent application by Ipsen Biopharm Ltd. for methods of treating metastatic pancreatic cancer using combination therapies with liposomal irinotecan and oxaliplatin. The application includes IPC classifications covering liposomal formulations (A61K 9/127, A61K 9/1271), irinotecan (A61K 31/475), oxaliplatin (A61K 31/282), and oncology applications (A61P 35/04). Designated states cover all major European markets.

This patent publication does not impose immediate compliance obligations on third parties. Competitors developing similar liposomal chemotherapy combinations for pancreatic cancer should review freedom-to-operate considerations. Generic manufacturers and biosimilar developers should monitor the prosecution of this application through the EPO grant process.

Source document (simplified)

← EPO Patent Bulletin

METHODS FOR TREATING METASTATIC PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN AND OXALIPLATIN

Publication EP3791876A1 Kind: A1 Mar 25, 2026

Applicants

Ipsen Biopharm Ltd.

Inventors

BLANCHETTE, Sarah, F., FITZGERALD, Jonathan, Basil, GADDY, Daniel, F., HENDRIKS, Bart, S., KALRA, Ashish, LEE, Helen, BAYEVER, Eliel

IPC Classifications

A61K 31/436 20060101AFI20251010BHEP A61P 35/04 20060101ALI20251010BHEP A61K 31/519 20060101ALI20251010BHEP A61K 31/513 20060101ALI20251010BHEP A61K 31/475 20060101ALI20251010BHEP A61K 31/4745 20060101ALI20251010BHEP A61K 31/282 20060101ALI20251010BHEP A61K 9/127 20060101ALI20251010BHEP A61K 9/00 20060101ALI20251010BHEP A61K 9/1271 20250101ALI20251010BHEP A61K 47/20 20060101ALI20251010BHEP A61P 43/00 20060101ALI20251010BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →